Fairchem Organics Ltd Q4 FY25 Earnings Analysis

- Management anticipates revenue to substantially grow with the commercialization of new high-value products, including isostearic acid and another new product with 40,000 MT capacity that could potentially double current sales. - Isostearic acid is expected to ramp up gradually, with approvals and marketing ongoing; full capacity utilization and significant export volumes projected within 2-3 years. - The new product commercialization is targeted within FY26, with plant installation completed and production costs/yields being optimized. - Market entry for these products will be gradual due to high product quality standards and long approval cycles, especially for export markets in cosmetics, pharmaceuticals, and biodegradable lubricants. - Domestic and export demand for isostearic acid is growing, with exports constituting nearly 90-100% of sales. - EBITDA margins are expected to improve to 12%-15% from FY26 due to higher contribution from value-added products and normalization of raw material duties. - Capacity expansion plans will only be considered after achieving full utilization of existing plants.

- Isostearic acid, a high-value, value-added product, is expected to significantly boost margins and revenues starting from April 2025. - Company expects EBITDA margins to improve to around 12%-15% from April 2025 onwards due to ramp-up of isostearic acid sales. - New product capacity of 40,000 tons, once commercialized, is expected to double the current sales on a high-value product basis. - Full utilization of new product capacity and isostearic acid ramp-up projected over 1.5-3 years, with commercial production starting potentially by FY26. - Operating profits and EPS expected to improve as import duty issues resolve and paint sector demand revives. - Export share, especially of isostearic acid, is increasing, boosting profitability further. - Management anticipates reaching full capacity and steady state in around 3 years post project initiation, leading to sustained earnings growth.

- The company has completed designing and obtained all permissions for new equipment. - Financial resources are available and include zero long-term debt; working capital and potential borrowing capacity up to Rs. 250 crores are accessible. - The next step is to place orders for the new equipment once manufacturing cost and yields are confidently optimized. - Plant setup timeline is estimated at 1 to 1.5 to 2 years. - After plant commissioning, it will take around 1.5 years for the product to complete the approval cycle. - Full capacity operations are expected within approximately three years after the final decision to proceed. - The approach is cautious to avoid massive cash losses from incorrect yields or cost issues. - No immediate plans to expand beyond achieving full capacity utilization in the near term.

- The company currently has zero long-term debt. - They have working capital facilities with an undrawn drawing power of approximately Rs. 60-75 crores. - They can withdraw Rs. 60-75 crores from working capital and can raise an additional Rs. 175 crores if needed, totaling up to Rs. 250 crores. - Money is not a problem for them, indicating capacity for raising funds if required. - However, there is no specific mention of an immediate or planned fundraising through debt or equity. - Focus currently is on optimizing manufacturing costs and operational efficiency before proceeding with new projects.

- The company has completed designing and obtained all necessary permissions for the new project. - Funding is in place; money is available for project execution. - The order placement for equipment is pending until the company is confident about manufacturing costs and yields. - Once confident, project implementation will take approximately 1 to 1.5-2 years. - After plant commissioning, the product will require about one cycle, and full capacity operation is expected within approximately 3 years from the decision to proceed. - No specific current orderbook or pending orders quantity is disclosed, as the focus is on readiness to scale after cost optimization.